A detailed history of Royal Bank Of Canada transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,524 shares of INZY stock, worth $16,185. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,524
Previous 5,297 4.29%
Holding current value
$16,185
Previous $23,000 21.74%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.31 - $6.0 $978 - $1,362
227 Added 4.29%
5,524 $28,000
Q2 2024

Aug 14, 2024

BUY
$4.33 - $7.31 $14,250 - $24,057
3,291 Added 164.06%
5,297 $23,000
Q1 2024

Nov 05, 2024

SELL
$4.14 - $7.66 $13,624 - $25,209
-3,291 Reduced 62.13%
2,006 $15,000
Q1 2024

May 15, 2024

SELL
$4.14 - $7.66 $54,217 - $100,315
-13,096 Reduced 86.72%
2,006 $15,000
Q4 2023

Feb 14, 2024

BUY
$2.71 - $4.5 $25,525 - $42,385
9,419 Added 165.74%
15,102 $64,000
Q3 2023

Nov 14, 2023

BUY
$4.09 - $7.0 $7,128 - $12,201
1,743 Added 44.24%
5,683 $23,000
Q2 2023

Aug 14, 2023

BUY
$4.93 - $6.74 $19,424 - $26,555
3,940 New
3,940 $21,000
Q3 2022

Nov 14, 2022

BUY
$2.57 - $5.45 $567 - $1,204
221 Added 47.12%
690 $2,000
Q2 2022

Aug 15, 2022

SELL
$3.2 - $5.96 $1,328 - $2,473
-415 Reduced 46.95%
469 $2,000
Q1 2022

May 16, 2022

SELL
$3.87 - $7.55 $8,231 - $16,058
-2,127 Reduced 70.64%
884 $4,000
Q4 2021

Feb 14, 2022

BUY
$5.58 - $11.5 $6,528 - $13,455
1,170 Added 63.55%
3,011 $20,000
Q3 2021

Nov 15, 2021

BUY
$11.12 - $19.4 $9,529 - $16,625
857 Added 87.09%
1,841 $21,000
Q2 2021

Aug 16, 2021

BUY
$15.19 - $21.2 $14,946 - $20,860
984 New
984 $17,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $118M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.